Drug Profile
Elsamitrucin
Alternative Names: BBM 2478A; BMY 28090; Elsamicin A; NSC 369327; SPI-28090Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Assertio Therapeutics
- Class Aminoglycosides; Benzopyrans; Cytostatic antibiotics
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 14 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
- 21 Apr 2011 Elsamitrucin is available for licensing in World (excluding USA) as of 21 Apr 2011. http://www.spectrumpharm.com/
- 21 Apr 2011 Phase-I clinical trials in late-stage Solid tumours (in combination with paclitaxel) in USA (IV) before April 2011